TABLE 8.
Univariate and multivariate analysis of prognostic factors for OS in patients with CSCC in the validation cohort.
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| p | HR (95% CI) | p | HR (95% CI) | |
| Age (≤45 vs. >45 years) | 0.120 | 0.352 (0.014–1.312) | ||
| FIGO stage (IB2-IIA2 vs. IIB) | 0.483 | 1.755 (0.356–8.454) | 0.528 | 1.744 (0.311–9.788) |
| Histological grade (G1-G2 vs. G3) | 0.555 | 0.673 (0.181–2.507) | 0.751 | 0.799 (0.200–3.195) |
| Tumor size (≤5 vs. >5 cm) | 0.282 | 2.059 (0.552–7.680) | 0.372 | 1.844 (0.480–7.081) |
| Tumor growth pattern (exogenous vs. endogenous) | 0.475 | 2.137 (0.267–17.128) | ||
| NACT cycles (≤2 vs. >2) | 0.628 | 1.384 (0.372–5.158) | 0.897 | 1.100 (0.260–4.654) |
| Adjuvant treatment (yes vs. no) | 0.803 | 0.768 (0.096–6.140) | ||
| SII (≤600.5683 vs. >600.5683) | 0.032 | 5.560 (1.155–26.776) | 0.042 | 5.143 (1.061–24.927) |
| PNI (≤49.5 vs. >49.5) | 0.500 | 1.717 (0.356–8.267) | ||
| PLR (≤153.4314 vs. >153.4314) | 0.651 | 1.354 (0.363–5.045) | ||
| LMR (≤12.25 vs. >12.25) | 0.729 | 1.320 (0.274–6.355) | ||
| Neutrophil (≤5.35 vs. >5.35) | 0.076 | 3.295 (0.884–12.277) | ||
| Lymphocyte (≤0.87 vs. >0.87) | — | — | ||
| Platelet (≤216 vs. >216) | 0.824 | 1.266 (0.158–10.125) | ||
CSCC, cervical squamous cell carcinoma; OS, overall survival; HR, hazard ratio; CI, confidence interval; NACT, neoadjuvant chemotherapy; SII, systemic immune-inflammation index; PNI, prognostic nutritional index; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.